ARTICLE | Company News
ICN, Metabasis HBV deal
October 2, 2001 7:00 AM UTC
ICN received a license from Metabasis (San Diego, Calif.) to develop and market MB6866, an oral prodrug to treat hepatitis B virus (HBV). ICN will fully fund development, and pay Metabasis a license f...